Tariffs, uncertainty and disruption: how drug makers and distributors can build operational supply chain resilience
Ryan Rotar, vice president of healthcare market strategy at Tecsys, outlines how supply chain resilience can be maintained in the …
Post
-
-
Eli Lilly to invest $3bn in China in anticipation of orforglipron approval
Eli Lilly is continuing its global investment drive to ensure it can meet future demand for its highly anticipated oral …
-
BioNTech co-founders step down to launch new mRNA venture
The co-founders of BioNTech will leave the company to launch a new mRNA-focused entity, amid mounting losses for the vaccine …
-
UK health authorities join forces to champion foreign infectious disease trials
Health divisions within the UK government and British non-profit organisations have banded together to support infectious disease trials in Africa, …
-
Idorsia and Pharmalink sign agreement to distribute Quviviq
Idorsia has signed an exclusive agreement with Pharmalink Drug Store to distribute and commercialise its Quviviq (daridorexant) insomnia therapy in …
-
Idorsia and Pharmalink sign agreement to distribute Quviviq
Idorsia has signed an exclusive agreement with Pharmalink Drug Store to distribute and commercialise its Quviviq (daridorexant) insomnia therapy in …
-
FDA approves GSK’s Wellcovorin for cerebral folate deficiency
The US Food and Drug Administration (FDA) has granted its approval for the expanded use of GSK’s Wellcovorin (leucovorin calcium) …
-
Peptides in the pipeline: How companies are overcoming the early-stage challenges
Much larger than traditional small molecule drugs, peptides enable rapid tissue penetration while retaining the selectivity and potency of a …
-
US vaccine manufacturers set to lose as RFK pushes for weaker vaccine mandates
Earlier this year, the Trump Administration, backed by US Health and Human Services Secretary Robert F Kennedy (RFK) Jr, a …
-
FDA homes in on biosimilar accessibility in new draft guidance
The US Food and Drug Administration (FDA) has further updated its regulatory framework around biosimilar medicines in a bid to …
-
Building for decades: Dubai’s long game in life sciences
Editor's note: This feature was reported in part prior to the escalation of hostilities in the Gulf, when Iran launched …
-
Junshi receives China’s NMPA acceptance for toripalimab injection
Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab subcutaneous injection (JS001sc) new drug applications (NDAs) …
-
Novo and Hims & Hers become partners to end legal feud
Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded …
-
NewcelX and Eledon partner for NCEL-101 programme
NewcelX has signed a collaborative research agreement with Eledon Pharmaceuticals to advance its NCEL-101 programme for type 1 diabetes (T1D). The …
-
GlobalData’s key thoughts from World EPA Congress 2026
GlobalData Healthcare recently attended the World Evidence, Pricing and Access (EPA) congress in Amsterdam on 3-4 March 2026. This conference …
